Medtech giant Boston Scientific has had the wind in its sails during the second quarter of 2021.
In Q2, it delivered a USD 3.08bn revenue, up against the predicted USD 2.94bn, and it had a 52.4 percent organic growth compared to the same time period last year.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.